BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36151963)

  • 1. Low-dose acyclovir for prophylaxis of varicella-zoster virus reactivation after hematopoietic stem cell transplantation in children.
    Tatebe Y; Ushio S; Esumi S; Sada H; Ochi M; Tamefusa K; Ishida H; Fujiwara K; Kanamitsu K; Washio K; Katsube R; Murakawa K; Zamami Y
    Pediatr Blood Cancer; 2022 Dec; 69(12):e29979. PubMed ID: 36151963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
    Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
    Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
    Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
    Kanda Y; Mineishi S; Saito T; Saito A; Yamada S; Ohnishi M; Chizuka A; Niiya H; Suenaga K; Nakai K; Takeuchi T; Makimoto A; Tanosaki R; Kami M; Tanaka Y; Fujita S; Watanabe T; Kobayashi Y; Tobinai K; Takaue Y
    Bone Marrow Transplant; 2001 Oct; 28(7):689-92. PubMed ID: 11704792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis--the incidence remains high.
    Blennow O; Fjaertoft G; Winiarski J; Ljungman P; Mattsson J; Remberger M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1646-9. PubMed ID: 24914821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Incidence of Varicella Zoster Virus Disease in Adults Receiving Single-Unit Cord Blood Transplantation.
    Fukushi K; Konuma T; Monna-Oiwa M; Isobe M; Kato S; Kuroda S; Takahashi S; Nannya Y
    Transplant Cell Ther; 2022 Jun; 28(6):339.e1-339.e7. PubMed ID: 35364334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation.
    Thomson KJ; Hart DP; Banerjee L; Ward KN; Peggs KS; Mackinnon S
    Bone Marrow Transplant; 2005 Jun; 35(11):1065-9. PubMed ID: 15806119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group.
    Oshima K; Takahashi T; Mori T; Matsuyama T; Usuki K; Asano-Mori Y; Nakahara F; Okamoto S; Kurokawa M; Kanda Y
    Transpl Infect Dis; 2010 Oct; 12(5):421-7. PubMed ID: 20626711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of varicella-zoster virus reactivation on the long-term outcomes of patients undergoing allogeneic hematopoietic stem cell transplantation.
    Li P; Li J; Huang H; Chen X; Lin Y; He G; Xu D
    J Health Popul Nutr; 2023 Oct; 42(1):105. PubMed ID: 37784192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Varicella zoster virus meningoencephalitis after allogeneic hematopoietic stem cell transplantation.
    Suzuki J; Ashizawa M; Okuda S; Wada H; Sakamoto K; Terasako K; Sato M; Kimura SI; Kikuchi M; Nakasone H; Kako S; Yamazaki R; Oshima K; Nishida J; Kanda Y
    Transpl Infect Dis; 2012 Aug; 14(4):E7-12. PubMed ID: 22340704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Varicella zoster virus infection after allogeneic hematopoietic cell transplantation in children using a relatively short duration of acyclovir prophylaxis: A retrospective study.
    Han SB; Kim SK; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH
    Medicine (Baltimore); 2017 Apr; 96(14):e6546. PubMed ID: 28383421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A predictive model of herpes zoster after allogeneic hematopoietic stem cell transplantation: VZV reactivation following antiviral prophylaxis discontinuation.
    Feng CJ; Zhao P; Fu HX; Yan CH; Wang CC; Zhu XL; He Y; Wang FR; Zhang YY; Mo XD; Kong Y; Han W; Wang JZ; Wang Y; Chen H; Chen YH; Zhao XY; Chang YJ; Xu LP; Liu KY; Huang XJ; Zhang XH
    Am J Hematol; 2024 Apr; 99(4):633-641. PubMed ID: 37772366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varicella Zoster Virus Infection in Children with Autologous Hematopoietic Cell Transplantation: A Retrospective, Single-Center Study in Korea.
    Kang JM; Kim JM; Lee JW; Yoo KH; Sung KW; Koo HH; Kim YJ
    Biol Blood Marrow Transplant; 2020 May; 26(5):965-971. PubMed ID: 31962166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation.
    Erard V; Guthrie KA; Varley C; Heugel J; Wald A; Flowers ME; Corey L; Boeckh M
    Blood; 2007 Oct; 110(8):3071-7. PubMed ID: 17515400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of acyclovir prophylaxis against varicella zoster virus disease after allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
    Wada-Shimosato Y; Tanoshima R; Hiratoko K; Takeuchi M; Tsujimoto SI; Shiba N; Ito S; Yamanaka T; Ito S
    Transpl Infect Dis; 2019 Jun; 21(3):e13061. PubMed ID: 30756465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation.
    Leung TF; Chik KW; Li CK; Lai H; Shing MM; Chan PK; Lee V; Yuen PM
    Bone Marrow Transplant; 2000 Jan; 25(2):167-72. PubMed ID: 10673675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features and risk factors for developing varicella zoster virus dissemination following hematopoietic stem cell transplantation.
    Umezawa Y; Kakihana K; Oshikawa G; Kobayashi T; Doki N; Sakamaki H; Ohashi K
    Transpl Infect Dis; 2014 Apr; 16(2):195-202. PubMed ID: 24438510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity.
    Vermont CL; Jol-van der Zijde EC; Hissink Muller P; Ball LM; Bredius RG; Vossen AC; Lankester AC
    Transpl Infect Dis; 2014 Apr; 16(2):188-94. PubMed ID: 24438482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Successful Treatment of a Cord Blood Transplant Recipient with Varicella Zoster Virus Meningitis, Radiculitis and Myelitis with Foscarnet.
    Shimizu R; Ohwada C; Nagao Y; Togasaki E; Kawajiri C; Muto T; Tsukamoto S; Sakai S; Takeda Y; Mimura N; Takeuchi M; Sakaida E; Iseki T; Nakaseko C
    Intern Med; 2017; 56(3):353-356. PubMed ID: 28154282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
    Fukushima T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Okazaki T; Nakajima H; Motoo Y; Umehara H
    Anticancer Res; 2012 Dec; 32(12):5437-40. PubMed ID: 23225448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.